Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -65.92x is in line with its 4-year average of -70.23x, near the high end of its 4-year range (-115.93x–-46.99x).
As of the fiscal period ended Friday, December 31, 2021. 18.62% below its 12-month average of -55.57x.
Reported quarterly interest coverage; no daily interpolation. Q4 FY2021 (2021-12-31): -65.92x.
INTEREST COVERAGE RATIO
-65.92x
INTEREST COVERAGE RATIO AVG TTM
-55.57x
INTEREST COVERAGE RATIO AVG 3Y
-70.23x
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-18.62%
CURRENT VS 3Y AVG
+6.14%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.44x
median of 527 covered companies
CURRENT VS SECTOR MEDIAN
-923.61%
vs the sector median at left
Foghorn Therapeutics Inc.
Market Cap
$115.67M
Interest Coverage Ratio
-65.92x
TTM Avg
-55.57x
3Y Avg
-70.23x
5Y Avg
N/A
Market Cap
$114.46M
Interest Coverage Ratio
-2256.36x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$113.89M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$113.77M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$117.76M
Interest Coverage Ratio
-405.70x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.94M
Interest Coverage Ratio
-415.73x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$118.59M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.57M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $115.67M | -65.92x | -55.57x | -70.23x | N/A |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | -2256.36x | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $113.89M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | N/A | N/A | N/A | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | -405.70x | N/A | N/A | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | -415.73x | N/A | N/A | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | N/A | N/A | N/A | N/A |
Interest Coverage
-65.9x
Debt/Equity
N/A
Current Ratio
3.36
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2021-12-31 | -65.92x |
| 2021-09-30 | -52.63x |
| 2021-06-30 | -46.99x |
| 2021-03-31 | -47.59x |
| 2020-12-31 | -64.73x |
| 2020-09-30 | -91.53x |
| 2020-06-30 | -78.48x |
| 2020-03-31 | -53.19x |
| 2019-12-31 | -85.31x |
| 2019-09-30 | -115.93x |
| 2018-06-30 | -70.21x |
| 2018-03-31 | -70.21x |
